Citation map · Study

SZodixStudyAcademic Library

Shelves Open access

Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated

Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China

11 references·1 citing·43 second hop

FromToDepth

this work references cited by second hop

References

1996Cost-Effectiveness in Health and Medicine7,192 cited
2000Development of WHO guidelines on generalized cost-effectiveness analysis578 cited
2008Health state utilities for non small cell lung cancer407 cited
2017Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States142 cited
2017ESMO International Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in countries outside of Europe124 cited
2018Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France72 cited
2018Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small cell lung cancer69 cited
2017Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma66 cited
2017Cost-effectiveness Analysis of Nivolumab for Treatment of Platinum-Resistant Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck63 cited
2018Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer63 cited
2015Perspectives on Cost and Value in Cancer Care51 cited

Cited by

2019Cost-effectiveness analysis of pembrolizumab monotherapy and chemotherapy in the non-small-cell lung cancer with different PD-L1 tumor proportion scores47 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work